
Hepion Pharmaceuticals Investor Relations Material
Latest events

Q4 2024
8 Apr, 2025

Q3 2024
14 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Hepion Pharmaceuticals Inc
Access all reports
Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company’s lead drug candidate, based on cyclophilin inhibition technology, aims to target inflammation, fibrosis, and viral infections affecting the liver. The company is headquartered in Edison, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
HEPA
Country
🇺🇸 United States